Enzyme replacement therapy in mucopolysaccharidosis VI: Evidence for immune responses and altered efficacy of treatment in animal models

Doug A. Brooks, Barbara M. King, Allison C. Crawley, Sharon Byers, John J. Hopwood

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Enzyme replacement therapy (ERT) can potentially result in an immunological response to the introduced protein. The immunological response by Mucopolysaccharidosis type VI (MPS VI) cats to recombinant human N-acetylgalactosamine 4-sulfatase (rh4S) ERT has been investigated. Plasma antibody titres to rh4S were detected in untreated MPS VI and normal control cats, but the antibody titres to rh4S were higher in ERT treated MPS VI cats. The reactivity by cats to rh4S did not appear to be just due to species cross reactivity, as plasma antibodies from normal control, MPS VI and MPS VI ERT cats reacted equally with feline and human 4-sulfatase. Normal control and MPS VI human plasma also had antibody titres to rh4S. Plasma antibodies to rh4S, from an ERT treated cat, could be temporarily removed from circulation by enzyme infusion, confirming specificity for rh4S and indicating a possible window for ERT in the absence of antibody. In enzyme distribution studies with 3H-rh4S, evidence of altered targeting, and enzyme inactivation and degradation were observed in high compared to low titre rats. In high titre rats, the observed loss of 3H-label from vacuolar organelles of the liver may represent either degradation of antibody bound 3H-rh4S for reutilisation within the liver, or antigen presentation. The development of high titre antibody may have a detrimental effect on the efficacy of ERT.

LanguageEnglish
Pages203-216
Number of pages14
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1361
Issue number2
DOIs
Publication statusPublished - 22 Aug 1997

Keywords

  • Antibody
  • Immune reaction
  • Lysosomal storage disease
  • Mucopolysaccharidosis VI
  • Treatment outcome

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Brooks, Doug A. ; King, Barbara M. ; C. Crawley, Allison ; Byers, Sharon ; Hopwood, John J. / Enzyme replacement therapy in mucopolysaccharidosis VI : Evidence for immune responses and altered efficacy of treatment in animal models. In: Biochimica et Biophysica Acta - Molecular Basis of Disease. 1997 ; Vol. 1361, No. 2. pp. 203-216.
@article{af760bef4c134250ad05a2bcd49a45a6,
title = "Enzyme replacement therapy in mucopolysaccharidosis VI: Evidence for immune responses and altered efficacy of treatment in animal models",
abstract = "Enzyme replacement therapy (ERT) can potentially result in an immunological response to the introduced protein. The immunological response by Mucopolysaccharidosis type VI (MPS VI) cats to recombinant human N-acetylgalactosamine 4-sulfatase (rh4S) ERT has been investigated. Plasma antibody titres to rh4S were detected in untreated MPS VI and normal control cats, but the antibody titres to rh4S were higher in ERT treated MPS VI cats. The reactivity by cats to rh4S did not appear to be just due to species cross reactivity, as plasma antibodies from normal control, MPS VI and MPS VI ERT cats reacted equally with feline and human 4-sulfatase. Normal control and MPS VI human plasma also had antibody titres to rh4S. Plasma antibodies to rh4S, from an ERT treated cat, could be temporarily removed from circulation by enzyme infusion, confirming specificity for rh4S and indicating a possible window for ERT in the absence of antibody. In enzyme distribution studies with 3H-rh4S, evidence of altered targeting, and enzyme inactivation and degradation were observed in high compared to low titre rats. In high titre rats, the observed loss of 3H-label from vacuolar organelles of the liver may represent either degradation of antibody bound 3H-rh4S for reutilisation within the liver, or antigen presentation. The development of high titre antibody may have a detrimental effect on the efficacy of ERT.",
keywords = "Antibody, Immune reaction, Lysosomal storage disease, Mucopolysaccharidosis VI, Treatment outcome",
author = "Brooks, {Doug A.} and King, {Barbara M.} and {C. Crawley}, Allison and Sharon Byers and Hopwood, {John J.}",
year = "1997",
month = "8",
day = "22",
doi = "10.1016/S0925-4439(97)00036-7",
language = "English",
volume = "1361",
pages = "203--216",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "2",

}

Enzyme replacement therapy in mucopolysaccharidosis VI : Evidence for immune responses and altered efficacy of treatment in animal models. / Brooks, Doug A.; King, Barbara M.; C. Crawley, Allison; Byers, Sharon; Hopwood, John J.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1361, No. 2, 22.08.1997, p. 203-216.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enzyme replacement therapy in mucopolysaccharidosis VI

T2 - Biochimica et Biophysica Acta - Molecular Basis of Disease

AU - Brooks, Doug A.

AU - King, Barbara M.

AU - C. Crawley, Allison

AU - Byers, Sharon

AU - Hopwood, John J.

PY - 1997/8/22

Y1 - 1997/8/22

N2 - Enzyme replacement therapy (ERT) can potentially result in an immunological response to the introduced protein. The immunological response by Mucopolysaccharidosis type VI (MPS VI) cats to recombinant human N-acetylgalactosamine 4-sulfatase (rh4S) ERT has been investigated. Plasma antibody titres to rh4S were detected in untreated MPS VI and normal control cats, but the antibody titres to rh4S were higher in ERT treated MPS VI cats. The reactivity by cats to rh4S did not appear to be just due to species cross reactivity, as plasma antibodies from normal control, MPS VI and MPS VI ERT cats reacted equally with feline and human 4-sulfatase. Normal control and MPS VI human plasma also had antibody titres to rh4S. Plasma antibodies to rh4S, from an ERT treated cat, could be temporarily removed from circulation by enzyme infusion, confirming specificity for rh4S and indicating a possible window for ERT in the absence of antibody. In enzyme distribution studies with 3H-rh4S, evidence of altered targeting, and enzyme inactivation and degradation were observed in high compared to low titre rats. In high titre rats, the observed loss of 3H-label from vacuolar organelles of the liver may represent either degradation of antibody bound 3H-rh4S for reutilisation within the liver, or antigen presentation. The development of high titre antibody may have a detrimental effect on the efficacy of ERT.

AB - Enzyme replacement therapy (ERT) can potentially result in an immunological response to the introduced protein. The immunological response by Mucopolysaccharidosis type VI (MPS VI) cats to recombinant human N-acetylgalactosamine 4-sulfatase (rh4S) ERT has been investigated. Plasma antibody titres to rh4S were detected in untreated MPS VI and normal control cats, but the antibody titres to rh4S were higher in ERT treated MPS VI cats. The reactivity by cats to rh4S did not appear to be just due to species cross reactivity, as plasma antibodies from normal control, MPS VI and MPS VI ERT cats reacted equally with feline and human 4-sulfatase. Normal control and MPS VI human plasma also had antibody titres to rh4S. Plasma antibodies to rh4S, from an ERT treated cat, could be temporarily removed from circulation by enzyme infusion, confirming specificity for rh4S and indicating a possible window for ERT in the absence of antibody. In enzyme distribution studies with 3H-rh4S, evidence of altered targeting, and enzyme inactivation and degradation were observed in high compared to low titre rats. In high titre rats, the observed loss of 3H-label from vacuolar organelles of the liver may represent either degradation of antibody bound 3H-rh4S for reutilisation within the liver, or antigen presentation. The development of high titre antibody may have a detrimental effect on the efficacy of ERT.

KW - Antibody

KW - Immune reaction

KW - Lysosomal storage disease

KW - Mucopolysaccharidosis VI

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=0030791383&partnerID=8YFLogxK

U2 - 10.1016/S0925-4439(97)00036-7

DO - 10.1016/S0925-4439(97)00036-7

M3 - Article

VL - 1361

SP - 203

EP - 216

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 2

ER -